A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

NCT03280030 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Midostaurin
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals